CLOVIS ONCOLOGY INC (CLVS) Stock Price, Quote, News and Overview
NASDAQ:CLVS - Nasdaq - US1894641000 - Common Stock - Currency: USD
CLVS Quote, Performance and Key Statistics
0.0812
0 (-5.58%)
The current stock price of CLVS is 0.0812 USD. In the past month the price decreased by -76.84%. In the past year, price decreased by -97.44%.
CLVS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CLVS
Company Profile
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. The company is headquartered in Boulder, Colorado and currently employs 413 full-time employees. The company went IPO on 2011-11-16. The firm is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). The company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).
Company Info
CLOVIS ONCOLOGY INC
Suite 100, 2525 28Th Street
Boulder COLORADO 80301 US
CEO: Patrick J. Mahaffy
Employees: 413
Company Website: https://clovisoncology.com/
Phone: 13036255000.0
CLOVIS ONCOLOGY INC / CLVS FAQ
What is the stock price of CLOVIS ONCOLOGY INC today?
The current stock price of CLVS is 0.0812 USD. The price decreased by -5.58% in the last trading session.
What is the ticker symbol for CLOVIS ONCOLOGY INC stock?
The exchange symbol of CLOVIS ONCOLOGY INC is CLVS and it is listed on the Nasdaq exchange.
On which exchange is CLVS stock listed?
CLVS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CLOVIS ONCOLOGY INC stock?
7 analysts have analysed CLVS and the average price target is 2.04 USD. This implies a price increase of 2412.32% is expected in the next year compared to the current price of 0.0812. Check the CLOVIS ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CLOVIS ONCOLOGY INC worth?
CLOVIS ONCOLOGY INC (CLVS) has a market capitalization of 11.77M USD. This makes CLVS a Nano Cap stock.
How many employees does CLOVIS ONCOLOGY INC have?
CLOVIS ONCOLOGY INC (CLVS) currently has 413 employees.
Is CLOVIS ONCOLOGY INC (CLVS) expected to grow?
The Revenue of CLOVIS ONCOLOGY INC (CLVS) is expected to decline by -14% in the next year. Check the estimates tab for more information on the CLVS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CLOVIS ONCOLOGY INC (CLVS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CLVS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CLVS, evaluating the profitability, health, valuation and growth aspects
- CLOVIS ONCOLOGY INC (CLVS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CLOVIS ONCOLOGY INC (CLVS) Sales and EPS estimates to see what analysts future expectations are.
- CLOVIS ONCOLOGY INC (CLVS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CLOVIS ONCOLOGY INC (CLVS) Insider and Institutional Ownership to learn about the owners and their transactions.
- CLOVIS ONCOLOGY INC (CLVS) Stock Chart to make your own analysis
- CLOVIS ONCOLOGY INC (CLVS) Latest news and press-releases to stay up to date.
Does CLOVIS ONCOLOGY INC (CLVS) stock pay dividends?
CLVS does not pay a dividend.
When does CLOVIS ONCOLOGY INC (CLVS) report earnings?
CLOVIS ONCOLOGY INC (CLVS) will report earnings on 2023-02-21.
What is the Price/Earnings (PE) ratio of CLOVIS ONCOLOGY INC (CLVS)?
CLOVIS ONCOLOGY INC (CLVS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.81).
CLVS Technical Analysis
CLVS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CLVS. Both the profitability and financial health of CLVS have multiple concerns.
CLVS Financial Highlights
Over the last trailing twelve months CLVS reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS increased by 36.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLVS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to CLVS. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 28.29% and a revenue growth -14% for CLVS